author-photo

Jonathan White

Charles River Laboratories

2

Papers

9

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.

2021 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (9)
Abstract 5014: Profile of ARX001822, a highly potent, selective and orally bioavailable A2a antagonist effective in preventing adenosinergic suppression of T cell activation

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)